Rchr
J-GLOBAL ID:201801018205306077   Update date: Jun. 09, 2024

Mimura Yoshihisa

ミムラ ヨシヒサ | Mimura Yoshihisa
Affiliation and department:
Research field  (1): Clinical pharmacy
Research keywords  (7): 骨転移 ,  ウェアラブルデバイス ,  前立腺がん ,  医療薬学 ,  消化管吸収 ,  transporter ,  pharmacokinetics
Research theme for competitive and other funds  (1):
  • 2020 - 2024 前立腺がんの新規骨転移予測法の開発-骨密度に着目した研究-
Papers (15):
  • Yoshihiko Tasaki, Shuzo Hamamoto, Taku Naiki, Toshiki Etani, Shoichiro Iwatsuki, Rei Unno, Takashi Nagai, Yoshihisa Mimura, Yosuke Sugiyama, Yuji Hotta, et al. MP10-06 ELEVATED EOSINOPHILS BEFORE 2 COURSE TREATMENT MAY BE A UNIVERSAL BIOMARKER FOR IMMUNE-RELATED ADVERSE EVENTS INDUCED BY COMMON TO DIFFERENT IMMUNE CHECKPOINT INHIBITOR AND CANCER TYPES INCLUDING TO UROLOGICAL CANCER. Journal of Urology. 2024. 211. 5S
  • Yoshihiko Tasaki, Nanami Ito, Yoshihisa Mimura, Yosuke Sugiyama, Ryo Ogawa, Takaya Shimura, Motoki Nakamura, Daisuke Kawakita, Shuzo Hamamoto, Takehiro Uemura, et al. Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients. Asia-Pacific journal of clinical oncology. 2024
  • Yoshihiko Tasaki, Yosuke Sugiyama, Shuzo Hamamoto, Taku Naiki, Takehiro Uemura, Keisuke Yokota, Daisuke Kawakita, Motoki Nakamura, Ryo Ogawa, Takaya Shimura, et al. Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study. Cancer medicine. 2023
  • Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Nami Tomiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura, et al. Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association. 2023. 30. 10. 866-874
  • Nami Tomiyama, Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura, et al. Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma. International Journal of Urology. 2023
more...
MISC (21):
  • 三村 佳久, 杉山 洋介, 小田切 州広, 田崎 慶彦, 飯田 萌子, 木村 優花, 伊藤 菜浪, 堀田 祐志, 内木 拓, 惠谷 俊紀, et al. Cachexia indexは転移性尿路上皮がん患者の予後予測因子となる. 日本癌治療学会学術集会抄録集. 2023. 61回. O40-1
  • 田崎 慶彦, 杉山 洋介, 伊藤 菜浪, 三村 佳久, 飯田 萌子, 小田切 州広, 木村 優花, 堀田 祐志, 内木 拓, 濱本 周造, et al. 好酸球は免疫チェックポイント阻害剤によるirAE発症の予測バイオマーカーとなる. 日本癌治療学会学術集会抄録集. 2023. 61回. MSA O58-3
  • 杉山 洋介, 内木 拓, 三村 佳久, 田崎 慶彦, 片岡 智哉, 小田切 州広, 飯田 萌子, 木村 優花, 伊藤 菜浪, 権田 将一, et al. オキシコドンの血中濃度の変化とがん性疼痛との関連性の検討. 日本癌治療学会学術集会抄録集. 2023. 61回. O58-5
  • 永井 隆, 内木 拓, 杉山 洋介, 惠谷 俊紀, 清水 伸彦, 三村 佳久, 野田 祐介, 阪野 里花, 窪田 裕樹, 濱本 周造, et al. mGPSは転移性尿路上皮癌患者の治療効果と予後を予測するマーカーである. 日本癌治療学会学術集会抄録集. 2023. 61回. P2-4
  • 伊藤 菜浪, 三村 佳久, 田崎 慶彦, 杉山 洋介, 飯田 萌子, 小田切 州広, 木村 優花, 堀田 祐志, 日比 陽子. ニボルマブの異なる投与スケジュールにおけるirAE発症プロファイルの解析. 日本癌治療学会学術集会抄録集. 2023. 61回. P45-5
more...
Education (2):
  • 2014 - 2018 Nagoya City University Graduate School of Pharmaceutical Sciences
  • 2008 - 2014 Nagoya City University Medicin Medicin
Work history (4):
  • 2023/04 - 現在 Graduate school of medical sciences, Nagoya city university Deparment of Clinical Pharmaceutics
  • 2018/04 - 現在 Nagoya City University
  • 2018/09 - 2023/04 Nagoya City University Graduate School of Pharmaceutical Sciences
  • 2018/03 - Nagoya City University Graduate School of Pharmaceutical Sciences
Committee career (1):
  • 2020/07 - 現在 愛知県病院薬剤師会 学術教育委員会
Association Membership(s) (3):
Japanese Society of Hospital Pharmacists ,  JAPANESE SOCIETY OF PHARMACEUTICAL HEALTH CARE AND SCIENCES ,  THE PHARMACEUTICAL SOCIETY OF JAPAN
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page